In 2015, Pfizer Inc. (New York, NY) and Merck Sharp & Dohme Corp. (Rahway, NJ) presented invention related to combination therapies useful for the treatment of cancer. In particular, the invention relates to a combination therapy, which comprises an antagonist of a Programmed Death 1 protein (PD-1) and an inhibitor of anaplastic lymphoma kinase (ALK).
In April 2020, Otsuka Pharmaceutical Co., Ltd. (Tokyo) patented invention related to an injectable preparation comprising 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt, which has a wide therapeutic spectrum for central nervous system diseases (particularly schizophrenia)
In June 2020, GlaxoSmithKline Biologicals SA patented invention related to immunogenic compositions such as vaccines, comprising immunogenic polypeptides from Haemophilus influenzae and Moraxella catarrhalis, which is used for boosting immune response.